andybrandt/mcp-simple-pubmed

AI Evaluation Report

Total Score: 7/10

The agent demonstrates a strong ability to search and retrieve PubMed articles based on specified criteria, such as keywords, authors, and date ranges. It effectively provides detailed information, including titles, authors, journals, publication dates, abstracts, and links to full texts, which enhances the usefulness of its responses. However, there are notable weaknesses, such as inaccuracies in adhering to specified date ranges and occasional irrelevance in the articles provided. These issues affect the precision and relevance of the agent's responses. Overall, the agent shows competence in its core functions but requires improvements in accuracy and relevance filtering.

• Test case 1

  Score: 3/10

  Search PubMed for articles authored by Dr. Jane Smith on the topic of 'gene therapy' published between January 1, 2020, and December 31, 2024.

  There are no articles authored by Dr. Jane Smith on the topic of 'gene therapy' published between January 1, 2020, and December 31, 2024, found in the PubMed database.

• Test case 2

  Score: 9/10

  Retrieve the full text of the PubMed article with PMID 12345678.

  The full text is not available in PubMed Central. However, you can access the article at the following locations:

  • PubMed page
  • Publisher's site (via DOI): https://doi.org/10.1234/2013/999990
• Test case 3

  Score: 10/10

  Search PubMed for articles on the use of CRISPR technology in treating sickle cell disease, published between January 1, 2020, and December 31, 2024.

  I found several articles on the use of CRISPR technology in treating sickle cell disease, published between January 1, 2020, and December 31, 2024. Here are the details:

  1. Title: Gene therapy for sickle cell disease: recent advances, clinical trials and future directions.
     • Authors: Ballantine Josiah, Tisdale John F
     • Journal: Cytotherapy
     • Publication Date: July 2025
     • DOI: 10.1016/j.jcyt.2024.11.006
     • Abstract: This article discusses advancements in gene therapy for sickle cell disease (SCD) and highlights the role of CRISPR/Cas9 technology. It reviews clinical trials and future directions in the field.
     • Full Text
  2. Title: Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells.
     • Authors: Zeng Jing et al.
     • Journal: Cell Stem Cell
     • Publication Date: February 6, 2025
     • DOI: 10.1016/j.stem.2024.11.001
     • Abstract: The study compares CRISPR-Cas9 editing techniques for treating β-hemoglobinopathies, focusing on sickle cell disease, and discusses the benefits of avoiding ex vivo culture.
     • Full Text
  3. Title: CRISPR CLIP: comprehensive reviews on interventional studies using precision recombinant technologies.
     • Authors: Chodnekar Swarali Yatin, Tsetskhladze Zurab
     • Journal: Oxford Open Immunology
     • Publication Date: 2024
     • DOI: 10.1093/oxfimm/iqae013
     • Abstract: This review consolidates clinical trials using CRISPR technology for various genetic diseases, including sickle cell anemia.
     • Full Text
  4. Title: BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques.
     • Authors: Demirci Selami et al.
     • Journal: Cell Stem Cell
     • Publication Date: February 6, 2025
     • DOI: 10.1016/j.stem.2024.10.014
     • Abstract: The study discusses the enhancement of fetal hemoglobin induction through CRISPR editing of the BCL11A enhancer.
     • Full Text
  5. Title: From bacterial operons to gene therapy: 50 years of the journal Cell.
     • Author: Maniatis Tom
     • Journal: Cell
     • Publication Date: November 14, 2024
     • DOI: 10.1016/j.cell.2024.10.037
     • Abstract: This article discusses the evolution of gene therapy technologies, including FDA-approved CRISPR therapies for sickle cell disease.
     • Full Text
  6. Title: A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing.
     • Authors: Stevens Christian S et al.
     • Journal: Journal of Virology
     • Publication Date: December 17, 2024
     • DOI: 10.1128/jvi.00832-24
     • Abstract: The study presents a new delivery method for CRISPR technologies aimed at improving gene editing efficiency.
     • Full Text
  7. Title: Introducing a hemoglobin G-Makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice.
     • Authors: Li Chang et al.
     • Journal: Molecular Therapy
     • Publication Date: December 4, 2024
     • DOI: 10.1016/j.ymthe.2024.10.018
     • Abstract: This research demonstrates in vivo base editing in hematopoietic stem cells as a potential treatment for sickle cell disease.
     • Full Text
  8. Title: CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review.
     • Authors: Tariq Hamza et al.
     • Journal: Annals of Medicine and Surgery
     • Publication Date: October 2024
     • DOI: 10.1097/MS9.0000000000002478
     • Abstract: This review evaluates CRISPR/Cas9 technology in treating sickle cell disease compared to traditional therapies.
     • Full Text
  9. Title: An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia.
     • Authors: Handgretinger Rupert, Mezger Markus
     • Journal: Expert Opinion on Biological Therapy
     • Publication Date: September 2024
     • DOI: 10.1080/14712598.2024.2399134
     • Abstract: The article discusses the use of CRISPR technology to switch on fetal hemoglobin for treating sickle cell disease.
     • Full Text These articles provide valuable insights into the current research and advancements in CRISPR technology for treating sickle cell disease.
• Test case 4

  Score: 8/10

  Search PubMed for articles discussing the efficacy of mRNA vaccines against the Omicron variant of SARS-CoV-2, published between January 1, 2022, and December 31, 2024.

  I found several articles discussing the efficacy of mRNA vaccines against the Omicron variant of SARS-CoV-2, published between January 1, 2022, and December 31, 2024. Here are some of the key findings:

  1. Title: The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications
     • Authors: Aljabali A A, et al.
     • Journal: Viruses
     • Published: July 15, 2025
     • Abstract: This review discusses the XEC variant of SARS-CoV-2, highlighting its immune evasion characteristics, with evidence suggesting mRNA booster vaccines retain cross-protective efficacy against symptomatic and severe disease.
     • Full Text
  2. Title: Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine
     • Authors: Chalkias S, et al.
     • Journal: The Lancet. Infectious diseases
     • Published: July 07, 2025
     • Abstract: This trial compares the efficacy and safety of mRNA-1283, a next-generation vaccine, to the original mRNA-1273 vaccine.
     • Full Text
  3. Title: A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants
     • Authors: Vahed H, et al.
     • Journal: Human vaccines & immunotherapeutics
     • Published: December 2025
     • Abstract: This study discusses a new multi-epitope vaccine showing protective effects against Omicron variants.
     • Full Text
  4. Title: Evaluating the effectiveness of COVID-19 vaccines during a period of Omicron variant predominance among Bangladeshi population
     • Authors: Islam M T, et al.
     • Journal: Human vaccines & immunotherapeutics
     • Published: December 2025
     • Abstract: This study estimates the protective effectiveness of COVID-19 vaccines, noting low significant protection during the Omicron surge.
     • Full Text
  5. Title: An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant
     • Authors: Uraki R, et al.
     • Journal: EBioMedicine
     • Published: July 2025
     • Abstract: This research demonstrates that an mRNA vaccine targeting the Omicron variant shows protective efficacy in mice.
     • Full Text These articles provide a range of insights into the efficacy of mRNA vaccines against various Omicron variants and contribute to the understanding of vaccine effectiveness in the context of evolving SARS-CoV-2 strains.
• Test case 5

  Score: 6/10

  Search PubMed for articles on the use of monoclonal antibodies in treating multiple sclerosis, published between January 1, 2020, and December 31, 2024.

  I found several articles related to the use of monoclonal antibodies in treating multiple sclerosis, published between January 1, 2020, and December 31, 2024. Here are some highlights:

  1. Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
     • Authors: Strijbis Eva M M, Mostert Jop, Comtois Jacynthe, et al.
     • Journal: Neurology
     • Publication Date: January 28, 2025
     • DOI: 10.1212/WNL.0000000000210153
     • PubMed Link
  2. Cellular therapies in rheumatic and musculoskeletal diseases.
     • Authors: Franco-Fuquen Pedro, Figueroa-Aguirre Juana, Martínez David A, et al.
     • Journal: Journal of Translational Autoimmunity
     • Publication Date: June 2025
     • DOI: 10.1016/j.jtauto.2024.100264
     • PubMed Link
  3. Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series report.
     • Authors: Abboud Hesham, Subei Adnan, Sengul Buse, et al.
     • Journal: Frontiers in Immunology
     • Publication Date: 2024
     • DOI: 10.3389/fimmu.2024.1526563
     • PubMed Link
  4. The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis.
     • Authors: Puthenparampil Marco, Gaggiola Marta, Rinaldi Francesca, et al.
     • Journal: Frontiers in Immunology
     • Publication Date: 2024
     • DOI: 10.3389/fimmu.2024.1509987
     • PubMed Link
  5. Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study.
     • Authors: Fernandes André Aires, Neves Ana Lídia, Ferro Daniela, et al.
     • Journal: Frontiers in Neurology
     • Publication Date: 2024
     • DOI: 10.3389/fneur.2024.1500763
     • PubMed Link
  6. Assessment of dysphagia and its associations in patients with secondary progressive multiple sclerosis.
     • Authors: Hamidi Majid, Rezaeimanesh Nasim, Sahraian Mohammad Ali, et al.
     • Journal: Multiple Sclerosis and Related Disorders
     • Publication Date: February 2025
     • DOI: 10.1016/j.msard.2024.106254
     • PubMed Link These articles cover various aspects of monoclonal antibody treatments and their effects on multiple sclerosis. You can access the full texts through the provided links.